Literature DB >> 30082890

Striatal dopamine D2 receptors regulate effort but not value-based decision making and alter the dopaminergic encoding of cost.

Ina Filla1, Matthew R Bailey2, Elke Schipani3,4, Vanessa Winiger3, Chris Mezias5, Peter D Balsam2,4,5, Eleanor H Simpson6,7.   

Abstract

Deficits in goal-directed motivation represent a debilitating symptom for many patients with schizophrenia. Impairments in motivation can arise from deficits in processing information about effort and or value, disrupting effective cost-benefit decision making. We have previously shown that upregulated dopamine D2 receptor expression within the striatum (D2R-OE mice) decreases goal-directed motivation. Here, we determine the behavioral and neurochemical mechanisms behind this deficit. Female D2R-OE mice were tested in several behavioral paradigms including recently developed tasks that independently assess the impact of Value or Effort manipulations on cost-benefit decision making. In vivo microdialysis was used to measure extracellular dopamine in the striatum during behavior. In a value-based choice task, D2R-OE mice show normal sensitivity to changes in reward value and used reward value to guide their actions. In an effort-based choice task, D2R-OE mice evaluate the cost of increasing the number of responses greater relative to the effort cost of longer duration responses compared to controls. This shift away from choosing to repeatedly execute a response is accompanied by a dampening of extracellular dopamine in the striatum during goal-directed behavior. In the ventral striatum, extracellular dopamine level negatively correlates with response cost in controls, but this relationship is lost in D2R-OE mice. These results show that D2R signaling in the striatum, as observed in some patients with schizophrenia, alters the relationship between effort expenditure and extracellular dopamine. This dysregulation produces motivation deficits that are specific to effort but not value-based decision making, paralleling the effort-based motivational deficits observed in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30082890      PMCID: PMC6135745          DOI: 10.1038/s41386-018-0159-9

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  56 in total

Review 1.  Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits.

Authors:  J D Salamone; M Correa; A Farrar; S M Mingote
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

2.  Prefrontostriatal circuitry regulates effort-related decision making.

Authors:  Wolfgang Hauber; Susanne Sommer
Journal:  Cereb Cortex       Date:  2009-01-08       Impact factor: 5.357

3.  Extracellular dopamine levels in striatal subregions track shifts in motivation and response cost during instrumental conditioning.

Authors:  Sean B Ostlund; Kate M Wassum; Niall P Murphy; Bernard W Balleine; Nigel T Maidment
Journal:  J Neurosci       Date:  2011-01-05       Impact factor: 6.167

4.  Nucleus accumbens dopamine depletions and time-constrained progressive ratio performance: effects of different ratio requirements.

Authors:  S Hamill; J T Trevitt; K L Nowend; B B Carlson; J D Salamone
Journal:  Pharmacol Biochem Behav       Date:  1999-09       Impact factor: 3.533

5.  Dopamine invigorates reward seeking by promoting cue-evoked excitation in the nucleus accumbens.

Authors:  Johann du Hoffmann; Saleem M Nicola
Journal:  J Neurosci       Date:  2014-10-22       Impact factor: 6.167

6.  Effect of quinolinic acid-induced lesions of the nucleus accumbens core on performance on a progressive ratio schedule of reinforcement: implications for inter-temporal choice.

Authors:  G Bezzina; S Body; T H C Cheung; C L Hampson; J F W Deakin; I M Anderson; E Szabadi; C M Bradshaw
Journal:  Psychopharmacology (Berl)       Date:  2008-01-03       Impact factor: 4.530

7.  A high-throughput screening procedure for identifying mice with aberrant taste and oromotor function.

Authors:  John I Glendinning; Jodi Gresack; Alan C Spector
Journal:  Chem Senses       Date:  2002-06       Impact factor: 3.160

8.  Negative symptoms of schizophrenia are associated with abnormal effort-cost computations.

Authors:  James M Gold; Gregory P Strauss; James A Waltz; Benjamin M Robinson; Jamie K Brown; Michael J Frank
Journal:  Biol Psychiatry       Date:  2013-02-07       Impact factor: 13.382

9.  Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning.

Authors:  Christoph Kellendonk; Eleanor H Simpson; H Jonathan Polan; Gaël Malleret; Svetlana Vronskaya; Vanessa Winiger; Holly Moore; Eric R Kandel
Journal:  Neuron       Date:  2006-02-16       Impact factor: 17.173

10.  Dissociation of hedonic reaction to reward and incentive motivation in an animal model of the negative symptoms of schizophrenia.

Authors:  Ryan D Ward; Eleanor H Simpson; Vanessa L Richards; Gita Deo; Kathleen Taylor; John I Glendinning; Eric R Kandel; Peter D Balsam
Journal:  Neuropsychopharmacology       Date:  2012-03-14       Impact factor: 7.853

View more
  12 in total

1.  Pharmacological studies of effort-related decision making using mouse touchscreen procedures: effects of dopamine antagonism do not resemble reinforcer devaluation by removal of food restriction.

Authors:  Jen-Hau Yang; Rose E Presby; Adam A Jarvie; Renee A Rotolo; R Holly Fitch; Mercè Correa; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2019-08-08       Impact factor: 4.530

Review 2.  Corticotropin-Releasing Factor (CRF) circuit modulation of cognition and motivation.

Authors:  Sofiya Hupalo; Courtney A Bryce; Debra A Bangasser; Craig W Berridge; Rita J Valentino; Stan B Floresco
Journal:  Neurosci Biobehav Rev       Date:  2019-06-15       Impact factor: 8.989

Review 3.  Vigor, Effort-Related Aspects of Motivation and Anhedonia.

Authors:  Michael T Treadway; John D Salamone
Journal:  Curr Top Behav Neurosci       Date:  2022

4.  Dopamine encodes real-time reward availability and transitions between reward availability states on different timescales.

Authors:  Abigail Kalmbach; Vanessa Winiger; Nuri Jeong; Arun Asok; Charles R Gallistel; Peter D Balsam; Eleanor H Simpson
Journal:  Nat Commun       Date:  2022-07-01       Impact factor: 17.694

5.  Quantifying the inverted U: A meta-analysis of prefrontal dopamine, D1 receptors, and working memory.

Authors:  Matthew A Weber; Mackenzie M Conlon; Hannah R Stutt; Linder Wendt; Patrick Ten Eyck; Nandakumar S Narayanan
Journal:  Behav Neurosci       Date:  2022-04-07       Impact factor: 2.154

Review 6.  Emerging roles of striatal dopamine D2 receptors in motivated behaviour: Implications for psychiatric disorders.

Authors:  Pedro R Olivetti; Peter D Balsam; Eleanor H Simpson; Christoph Kellendonk
Journal:  Basic Clin Pharmacol Toxicol       Date:  2019-06-28       Impact factor: 4.080

Review 7.  How changes in dopamine D2 receptor levels alter striatal circuit function and motivation.

Authors:  Eleanor H Simpson; Eduardo F Gallo; Peter D Balsam; Jonathan A Javitch; Christoph Kellendonk
Journal:  Mol Psychiatry       Date:  2021-08-12       Impact factor: 13.437

8.  Overexpression of striatal D2 receptors reduces motivation thereby decreasing food anticipatory activity.

Authors:  Joseph LeSauter; Peter D Balsam; Eleanor H Simpson; Rae Silver
Journal:  Eur J Neurosci       Date:  2018-11-26       Impact factor: 3.386

9.  Chronic social defeat stress impairs goal-directed behavior through dysregulation of ventral hippocampal activity in male mice.

Authors:  Keitaro Yoshida; Michael R Drew; Anna Kono; Masaru Mimura; Norio Takata; Kenji F Tanaka
Journal:  Neuropsychopharmacology       Date:  2021-03-10       Impact factor: 7.853

10.  Dopamine D2R upregulation in ventral striatopallidal neurons does not affect Pavlovian or go/no-go learning.

Authors:  Kelly M Martyniuk; Michelle Dandeneau; Peter D Balsam; Christoph Kellendonk
Journal:  Behav Neurosci       Date:  2021-06       Impact factor: 2.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.